Skip to content

CDR

Nambe Drugs now offers AllerPops for allergy sufferers

Nambe Drugs now offers AllerPops for allergy sufferers

Nambe Drugs, a family-owned pharmacy located in Los Alamos and Santa Fe, is now carrying AllerPops, a natural allergy remedy that works by correcting the underlying cause of allergies instead of masking the symptoms. “I think it’s going to be a very effective product.

Pharmacy coalition applauds drug pricing act

Pharmacy coalition applauds drug pricing act

A coalition of national pharmacy groups on Tuesday applauded the latest version of the bipartisan Prescription Drug Pricing Reduction Act, released Friday by the Senate Finance Committee, which they say addresses backdoor clawback fees charged by large pharmacy benefit managers (PBMs) that are shutt

Frito-Lay and Feed the Children team up

Frito-Lay and Feed the Children team up

For the second year, a partnership between Frito-Lay and Feed the Children will provide El Paso families, pre-identified by Destiny Family Christian Center, with enough food and daily essentials to supplement meals for a week. The event kicks off Tuesday, Dec. 10, at 11 a.m.

Diplomat Pharmacy agrees to $300 million buyout by UnitedHealth

Diplomat Pharmacy agrees to $300 million buyout by UnitedHealth

UnitedHealth Group pharmacy benefit manager OptumRx on Monday announced plans to purchase specialty drug provider Diplomat Pharmacy Inc. for about $300 million. The news comes amid continued financial struggles for Diplomat. In the third quarter, the company reported a $177 million net loss.

Snickers permanently rolls out white chocolate variety

Snickers permanently rolls out white chocolate variety

The Snickers Brand reintroduced on Monday a favorite twist on their iconic chocolate bar with Snickers White. Snickers White features the same delicious ingredients of the beloved bar—including the same peanuts, nougat and caramel—but fully covered in rich, white chocolate.

Merck to buy ArQule, advancing leadership in oncology

Merck to buy ArQule, advancing leadership in oncology

Merck and ArQule announced Monday that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire ArQule for $20 per share in cash for an approximate total equity value of $2.7 billion.